Zacks Research Issues Positive Outlook for Novartis Earnings

Key Points

• Zacks Research raised its FY2026 earnings estimate for Novartis to $8.83 per share from $8.82, near the $8.85 consensus forecast. It also projected $2.40 EPS for Q4 2027 and $2.72 EPS for Q2 2028.
• Novartis reported quarterly EPS of $2.41 on revenue of $14.95 billion, with a 23.29% net margin and 38.56% return on equity.
• Analyst sentiment remains mixed, with seven Buy, seven Hold and two Sell ratings; the consensus rating is Hold and the average price target is $141.20. Shares opened at $158.00, down 0.5%.

Novartis AG (NYSE:NVS - Free Report) - Research analysts at Zacks Research boosted their FY2026 earnings per share estimates for shares of Novartis in a report released on Monday, August 24th. Zacks Research analyst Team now expects that the company will earn $8.83 per share for the year, up from their previous forecast of $8.82. The consensus estimate for Novartis' current full-year earnings is $8.85 per share. Zacks Research also issued estimates for Novartis' Q4 2027 earnings at $2.40 EPS and Q2 2028 earnings at $2.72 EPS.

Novartis (NYSE:NVS - Get Free Report) last released its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. The company had revenue of $14.95 billion during the quarter.

Other equities research analysts also recently issued reports about the stock. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Novartis in a research note on Friday, July 24th. Citigroup reissued a "buy" rating on shares of Novartis in a research report on Wednesday, July 22nd. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $141.20.

Novartis Stock Down 0.5%

Shares of NYSE NVS opened at $158.00 on Tuesday. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.89. The firm has a market cap of $301.48 billion, a PE ratio of 23.83, a P/E/G ratio of 2.72 and a beta of 0.45. The company's fifty day simple moving average is $154.48 and its 200 day simple moving average is $153.72. Novartis has a 12-month low of $121.57 and a 12-month high of $170.46.

Hedge Funds Weigh In On Novartis

A number of institutional investors have recently modified their holdings of the company. Brighton Jones LLC raised its holdings in Novartis by 76.5% during the fourth quarter. Brighton Jones LLC now owns 6,153 shares of the company's stock worth $599,000 after buying an additional 2,666 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Novartis by 102.8% during the first quarter. AQR Capital Management LLC now owns 22,573 shares of the company's stock valued at $2,516,000 after buying an additional 11,444 shares during the last quarter. Empowered Funds LLC bought a new stake in shares of Novartis during the first quarter worth about $1,764,000. Sivia Capital Partners LLC increased its position in shares of Novartis by 48.0% during the second quarter. Sivia Capital Partners LLC now owns 7,959 shares of the company's stock worth $963,000 after acquiring an additional 2,581 shares in the last quarter. Finally, Schnieders Capital Management LLC. acquired a new stake in shares of Novartis in the 2nd quarter worth about $202,000. 13.12% of the stock is owned by institutional investors and hedge funds.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company's activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source